Orchard Collaborates with Pharming to Develop and Commercialize OTL-105 for Hereditary Angioedema

Shots:

• Orchard to receive $17.5M up front including $10M in cash & $7.5M as equity investment at a premium to Orchard’s share and is also eligible to receive ~$189.5M as other milestones along with royalties on WW sales
• Pharming has granted WW rights to OTL-105 (ex vivo HSC gene therapy) & will be responsible for clinical development, regulatory filings & commercialization of OTL-105 including associated costs
• Orchard will responsible for the completion of IND-enabling activities and manufacture OTL-105 in pre/ clinical development. Additionally, the companies will investigate the application of non-toxic conditioning regimen for OTL-105 administration

Click here to­ read full press release/ article | Ref: Orchard | Image: Twitter